AUTL NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Autolus Therapeutics Ltd · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 1.45 USD
0.7% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -5.6% below the Trend Line and sits at 19.3% of its 52-week range. The latest completed week returned 0.7%, after a -9.9% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers. Options positioning is volatility with 60/100 conviction, while the latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.

Setup score 23 out of 100
Latest Close 1.45 USD 24 Jul 2026
1W Return 0.7% latest completed week
4W Return -9.9% short-term follow-through
12W Return -1.4% quarterly tape
Trend Breadth 17.3% 9 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.7% Latest completed week; four-week move -9.9%. Indicator stack 10/41 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 60/100 conviction; expected move 35.7%. News sentiment 52/100 58 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -5.6% below the Trend Line and sits at 19.3% of its 52-week range. The latest completed week returned 0.7%, after a -9.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3312-week average 0.22

12-week confirmation

Trend active5/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.33Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -9.9% over four weeks, -1.4% over 12 weeks, and -42.5% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W0.7%
4W-9.9%
12W-1.4%
26W-0.7%
52W-42.5%
Active trend streak0 weeks
Active weeks in one year9
Trend breadth17.3%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.03Latest activity-pressure read.
Pressure change-107.0%Four-week change in activity pressure.
Leadership-15.29Latest relative-leadership reading.
RS change-3.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength2/100Blend of value, momentum, and quality. Underlying universe rank 99; rank 1 is best.
Value21/100Relative valuation strength. Underlying universe rank 80; rank 1 is best.
Quality1/100Profitability and accounting quality. Underlying universe rank 100; rank 1 is best.
Momentum8/100Medium-term price momentum. Underlying universe rank 93; rank 1 is best.
Growth91/100Revenue and earnings growth. Underlying universe rank 10; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
4.2x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-66.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-11.2%
Gross profit retained from each unit of revenue.
Operating margin
-263.3%
Operating profit retained from revenue.
Free-cash-flow margin
-242.0%
Free cash flow generated from revenue.
Return on invested capital
-316.0%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
927.5%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

AUTL shows volatility options pressure with a 60/100 conviction score, put-call volume ratio of 0.00, expected move of 35.7%, and Sharemaestro trend signal inactive.

Conviction60/100
Expected move35.7%
Put/call volume0.00
Pressure100
Speculation40
Volatility96
Trend agreement0
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 58 relevant articles.

13 positive · 40 neutral · 5 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move35.7%Nearest-chain priced movement where available.
52-week drawdown-44.2%Distance below the 52-week high.
13-week volatility7.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+19.3%Week of 20 Feb.
Worst week-18.2%Week of 5 Jun.
Latest week+0.7%Week of 24 Jul.

Shape of recent returns

Strong gains8
Modest gains7
Flat weeks0
Modest losses3
Sharp losses8
Recent vol7.3%13-week weekly-return volatility.
Base vol9.3%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew6.3% / -8.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape23/100

Trend, activity pressure, participation, and risk combine to a 23/100 tape read.

 Indicator analysis44/100

Latest 12-week confirmation: trend 5/12, activity pressure 11/12, relative leadership 0/12.

Activity pressure 0.33; No reversal markers Factors6/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 55; Small Cap Core rank 78 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options38/100

AUTL shows volatility options pressure with a 60/100 conviction score, put-call volume ratio of 0.00, expected move of 35.7%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 35.7% Sentiment52/100

Weighted news tone is neutral across 58 relevant articles.

AUTL|Autolus Therapeutics PLC|Price:1.450|Chg%:-0.070 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20261.45 USD0.7%1.54 USD2.89 USD-0.03-15.293.9MOff
17 Jul 20261.44 USD-10.6%1.54 USD2.90 USD0.33-18.688.4MOff
10 Jul 20261.61 USD1.9%1.55 USD2.91 USD0.42-14.315.9MOn
3 Jul 20261.58 USD-1.9%1.55 USD2.91 USD0.40-15.804.2MOff
26 Jun 20261.61 USD6.6%1.55 USD2.92 USD0.37-14.744.8MOff
19 Jun 20261.51 USD-3.2%1.54 USD2.92 USD0.49-24.694.0MOff
12 Jun 20261.56 USD2.0%1.53 USD2.93 USD0.76-21.165.9MOn
5 Jun 20261.53 USD-18.2%1.53 USD2.94 USD0.92-21.927.5MOn
29 May 20261.87 USD10.0%1.52 USD2.95 USD1.03-10.276.6MOn
22 May 20261.70 USD4.3%1.51 USD2.95 USD0.83-16.5510.3MOn
15 May 20261.63 USD3.8%1.50 USD2.96 USD0.52-19.388.9MOff
8 May 20261.57 USD6.8%1.50 USD2.97 USD0.31-22.748.3MOff
1 May 20261.47 USD2.1%1.51 USD2.97 USD0.03-23.945.4MOff
24 Apr 20261.44 USD-10.0%1.51 USD2.98 USD-0.12-24.645.6MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.